All About Multiple Sclerosis

More MS news articles for October 2003

Questcor to Present at Rodman & Renshaw Techvest Healthcare Conference

http://home.businesswire.com/portal/site/google/index.jsp?ndmViewId=news_view&newsId=20031016005600&newsLang=en

October 16, 2003 04:30 PM US Eastern Timezone
Business Wire
Union City, Calif.

Charles J. Casamento, Chairman, President and CEO of Questcor Pharmaceuticals, Inc. will give a presentation to investors at the Rodman and Renshaw Techvest Healthcare Conference. The presentation will include a discussion of the Company's recent launch of its sales and promotional campaign for Acthar(R) used for the treatment of flares associated with Multiple Sclerosis and developments regarding the newly acquired product Nascobal(R), a nasal gel formulation of Vitamin B-12. The conference will be held at the Boston Marriot Long Wharf Hotel, October 21-23, 2003. Mr. Casamento will make his presentation on Wednesday, October 22, 2003 at 4:00 p.m. EST.

This presentation will also be webcast and can be accessed through the following link, http://www.wallstreetwebcasting.com/webcast/rrshq/qsc/ or by visiting Questcor's web site, for up to two weeks following the event, at www.questcor.com.

About Questcor

Questcor Pharmaceuticals, Inc. is a specialty pharmaceutical company that acquires, develops, markets and sells brand name prescription drugs through a U.S. direct sales force and overseas distributors. Questcor currently markets five products in the U.S.: HP Acthar(R) Gel, an injectable drug that is commonly used in treating patients with infantile spasm and is approved for the treatment of certain central nervous system disorders with an inflammatory component including the treatment of flares associated with Multiple Sclerosis; Nascobal(R), a nasal gel formulation of Cyanocobalamin USP (Vitamin B-12), that is approved for patients with severe deficiencies of Vitamin B-12 caused by MS and Crohn's Disease; Ethamolin(R), an injectable drug used to treat enlarged weakened blood vessels at the entrance to the stomach that have recently bled, known as esophageal varices; Glofil(R)-125, which is an injectable agent that assesses how well the kidney is working by measuring glomerular filtration rate, or kidney function; and VSL#3(TM), a patented probiotic marketed as a dietary supplement, to promote normal gastrointestinal (GI) function. As part of a strategy to develop its products globally, Questcor has entered into several contractual relationships with public and private companies including: Ahn-Gook Pharmaceuticals of Korea; Aventis Pharmaceuticals Inc. of Bridgewater, NJ; Beacon Pharmaceuticals, Ltd. of Tunbridge Wells, Kent, United Kingdom; Dainippon Pharmaceutical Co. Ltd., of Osaka, Japan; Nastech Pharmaceutical Company Inc. of Bothell, WA; Orphan Australia of Melbourne, Australia and VSL Pharmaceuticals of Ft. Lauderdale, FL.

Note: Except for the historical information contained herein, this press release contains forward-looking statements that involve risks and uncertainties. Such statements are subject to certain factors, which may cause Questcor's results to differ from those reported herein. Factors that may cause such differences include, but are not limited to, Questcor's ability to accurately forecast the demand for each of their products, the gross margins achieved from the sale of those products, the accuracy of the prescription data purchased from independent third parties by Questcor, the sell through by Questcor's distributors, the inventories carried by Questcor's distributors, and the expenses and other cash needs for the upcoming periods, Questcor's ability to obtain finished goods from its sole source contract manufacturers on a timely basis if at all, Questcor's need for additional funding, uncertainties regarding Questcor's intellectual property and other research, development, marketing and regulatory risks, and, to the ability of Questcor to implement its strategy and acquire products and, if acquired, to market them successfully as well as the risks discussed in Questcor's report on Form 10-K for the calendar year ended December 31, 2002 and other documents filed with the Securities and Exchange Commission. The risk factors and other information contained in these documents should be considered in evaluating Questcor's prospects and future financial performance.

The Company undertakes no obligation to publicly release the result of any revisions to these forward-looking statements, which may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
 

Copyright © 2003, Business Wire